<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335606</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-440</org_study_id>
    <nct_id>NCT02335606</nct_id>
  </id_info>
  <brief_title>Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan</brief_title>
  <official_title>Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Multi-center Observational Study in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abatacept Registry in Taiwan
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 6, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The retention rate of abatacept therapy over 24 months in RA patients under real world clinical practice in Taiwan.</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>Treatment retention rate is defined as the proportion of subjects who use abatacept for 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The retention rate (%) of abatacept therapy at 6, 9, 12, and 18 months in RA patients</measure>
    <time_frame>at 6, 9, 12, 18, and 24months after study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to treatment discontinuation in RA patients treated with abatacept</measure>
    <time_frame>at 6, 9, 12, 18, and 24months after study participation</time_frame>
    <description>Treatment discontinuation is defined as patients who cease treatment for &gt; 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving DAS28 ≤ 2.6, 2.6 &lt; DAS28 ≤ 3.2, 3.2 &lt; DAS28 ≤ 5.1, DAS&gt; 5.1 at 6, 9, 12, 18, and 24months</measure>
    <time_frame>at 6, 9, 12, 18, and 24months after study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The major reason for treatment discontinuation (eg, lack of efficacy, severe adverse drug reactions, switch from abatacept to another RA medication, financial issues, etc) at 6, 9, 12, 18, and 24 months</measure>
    <time_frame>at 6, 9, 12, 18, and 24months after study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The demographic, clinical presentation, and disease management a composite measure of RA patients who are using abatacept (either formulation) or are abatacept naïve at Month 6, 9, 12, 18, and 24</measure>
    <time_frame>at 6, 9, 12, 18, and 24months after study participation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients treating with Abatacept</arm_group_label>
    <description>Patients who are abatacept naive and are initiating abatacept treatment (either IV or SC) including those that are switching from another bDMARD, as well as, patients currently being treated with IV or SC abatacept some of which may have switched from IV abatacept to SC abatacept</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital : Research based hospital centers, Teaching hospitals affiliated with medical
        schools, National/Regional medical centers and/or in which thought leaders are employed
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  ≥ 20 years of age

          -  Who give informed consent

          -  Confirmed diagnosis of RA (as defined by American College of Rheumatology revised 1987
             criteria) and has ≥ 4 of the criteria listed below for ≥6 weeks before study
             enrollment

          -  Who self-pay or who are reimbursed by BNHI for abatacept treatment

          -  With latent TB or who are receiving anti-TB treatment (INH 300 mg, QD) 1 month prior
             to using abatacept and continuously up to a total of 9 months Willing to follow Taiwan
             Risk Management Plan guidelines as required by Taiwan health authorities

          -  Are being treated with abatacept or are abatacept treatment naïve and are initiating
             abatacept therapy

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  With active TB

          -  HBsAg (+)and/or Anti-HCV(+) and/or HBV DNA(+)

          -  Have cancer (patients who were treated and have no sign of cancer for &gt; 10 years can
             be included)

          -  Are allergic to abatacept

          -  Enrolled in other RA clinical studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <zip>105</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

